Skip to content
10-Q

Quarterly Report

NUTRA PHARMA CORP. NPHC

0001493152-25-028946

← back to feed
Filed
Dec 23, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2024 · Dec 23, 2025 7.1B sh
Long Term Debt Q2 2024 · Jun 30, 2024 $141.95K
Short Term Debt Q2 2024 · Jun 30, 2024 $8.32M
Short Term Debt Q2 2024 · Dec 31, 2023 $8.33M
Short Term Investments Q2 2024 · Jun 30, 2024 $17.6K
Short Term Investments Q2 2024 · Dec 31, 2023 $35.2K
Cash And Equivalents Q2 2024 · Jun 30, 2024 $0
Cash And Equivalents Q2 2024 · Dec 31, 2023 $0
Current Liabilities Q2 2024 · Jun 30, 2024 $15M
Current Liabilities Q2 2024 · Dec 31, 2023 $14.17M
Total Liabilities Q2 2024 · Jun 30, 2024 $15.19M
Total Liabilities Q2 2024 · Dec 31, 2023 $14.41M
Current Assets Q2 2024 · Jun 30, 2024 $359.89K
Current Assets Q2 2024 · Dec 31, 2023 $314.06K
Total Assets Q2 2024 · Jun 30, 2024 $630.97K
Total Assets Q2 2024 · Dec 31, 2023 $640.4K
Shares Diluted Q2 2024 · Jun 30, 2023 7.6B sh
Shares Diluted Q2 2024 · Jun 30, 2023 7.6B sh
Operating Cash Flow Q2 2024 · Jun 30, 2023 −$279.62K
Stockholders Equity Q2 2024 · Jun 30, 2023 −$13.25M
Stockholders Equity Q2 2024 · Mar 31, 2023 −$12.97M
Stockholders Equity Q2 2024 · Dec 31, 2022 −$12.38M
Eps Diluted Q2 2024 · Jun 30, 2023 $0.00
Eps Diluted Q2 2024 · Jun 30, 2023 $0.00
Eps Basic Q2 2024 · Jun 30, 2023 $0.00
Eps Basic Q2 2024 · Jun 30, 2023 $0.00
Sga Expense Q2 2024 · Jun 30, 2023 $266.94K
Sga Expense Q2 2024 · Jun 30, 2023 $663.26K
Net Income Q2 2024 · Jun 30, 2023 −$279.25K
Net Income Q2 2024 · Jun 30, 2023 −$871.81K
Operating Income Q2 2024 · Jun 30, 2023 −$182.3K
Operating Income Q2 2024 · Jun 30, 2023 −$580.99K
Gross Profit Q2 2024 · Jun 30, 2023 $84.64K
Gross Profit Q2 2024 · Jun 30, 2023 $187.73K
Revenue Q2 2024 · Jun 30, 2023 $52.4K
Revenue Q2 2024 · Jun 30, 2023 $106.92K